Touchlight

With higher HDR efficiency, lower toxicity and scalable production,mbDNA™ is a breakthrough in non-viral, single-stranded DNA (ssDNA) technology. Reset your benchmark for gene therapy innovation. Get the expert insights here: eu1.hubs.ly/H0vGFFG0

We’re heading to #BIO2026! Meet the Touchlight team in the UK Pavilion at Booth #2221, & learn how cell‑free DNA manufacturing is helping customers overcome challenges in genetic medicines. Learn more or schedule a meeting today here: eu1.hubs.ly/H0vF5rm0

Non-viral delivery workflows continue to push the limits of plasmid DNA systems. This analysis explores how alternative DNA architectures may improve in vivo protein expression and durability in non-viral delivery applications. Access it here: eu1.hubs.ly/H0vxP050

Producing high-quality RNA is essential for the success of #RNA-based therapeutics. This application note explores how IVT template quality may impact RNA purity, dsRNA content, and manufacturing consistency. Get the insights, access it here: eu1.hubs.ly/H0vscHs0 #cellfreedna

LVV manufacturing timelines continue to slow many cell & gene therapy programs. Plasmid workflows can introduce variability, complexity, and scale-up challenges. Explore strategies for streamlining LVV production and accelerating path-to-clinic timelines: eu1.hubs.ly/H0vq1_w0

Gene editing workflows often force tradeoffs between HDR efficiency, toxicity, and scalability. Explore how mbDNA™ may help researchers improve non-viral ssDNA editing workflows and overcome limitations of traditional templates. Read the article: eu1.hubs.ly/H0vm1jt0

At #ASGCT26, Touchlight and @SartoriusGlobal shared new insights into how mbDNA™ and non-viral delivery solutions may improve editing outcomes. Visit booth #1334 today + explore our 3 posters on display. Get all the details and book a meeting here: eu1.hubs.ly/H0vkMwB0

Whether you’re developing gene therapies, mRNA vaccines, or cell-based treatments, our technologies provide speed, purity & flexibility you need to advance your program from discovery to commercialisation. Let us help move your program forward, faster: eu1.hubs.ly/H0vjjDg0

Where does plasmid DNA still win, and where does cell-free DNA outperform? Watch as experts break down real-world data and what it means for next-generation gene therapy. Get the insights today in this on-demand webcast. eu1.hubs.ly/H0vggD60

We’re bringing new science, trending data, & big ideas to #ASGCT! Hear the latest cell-free DNA advancements, during the event, visit our 3 posters & hear an oral Presentation on Lipid-Based Formulations for Cell Free single stranded delivery on 5/13: eu1.hubs.ly/H0vgs0Q0

Join us at #ASGCT2026 this week! Touchlight is on site at booth 1334. Come see how our cell‑free DNA technologies are helping developers move faster and overcome the limitations of plasmid DNA. Learn more or request a meeting: eu1.hubs.ly/H0vcgyQ0 #DNAManufacturing

Touchlight will be exhibiting at booth 1713 at #ISCT2026 in Dublin (6–9 May). Don't miss our abstract presentation: “Reimagining DNA payloads; enzymatic circular DNA for the next generation of cell and gene therapies.” Request a meeting here: eu1.hubs.ly/H0v7l5s0

Touchlight will be exhibiting at booth 1713 at #ISCT2026 in Dublin (6–9 May) and presenting our latest abstract: “Reimagining DNA payloads; enzymatic circular DNA for the next generation of cell and gene therapies.” Request a meeting here: eu1.hubs.ly/H0v4Tkm0

We’re delighted to welcome Will Downie to Touchlight's Board of Directors. Bringing a wealth of leadership experience, his insight into pharma outsourcing and strategic growth will be an invaluable asset as we grow. Learn more about our leadership team: eu1.hubs.ly/H0v3l5B0

Plasmid DNA has long been central to cell and gene therapy development. As manufacturing demands scale, many developers are re‑evaluating whether pDNA is still the best fit for speed, consistency, and long‑term resilience. Get insights in this Q&A article eu1.hubs.ly/H0v1dF80

Touchlight will be exhibiting at booth 1713 at #ISCT2026 in Dublin (6–9 May) and presenting our latest abstract: “Reimagining DNA payloads; enzymatic circular DNA for the next generation of cell and gene therapies.” Request a meeting here: eu1.hubs.ly/H0t_-3j0

Join us in Seoul at #BIOKOREA2026, where global bio‑health leaders connect to shape the future of advanced therapies. Meet our team and discuss how our cell-free DNA can help your advanced therapy development. eu1.hubs.ly/H0tWwf40

Two leading experts go head‑to‑head in The Great DNA Debate: Plasmid vs. Cell‑Free DNA, unpacking real‑world data, practical use cases, and fresh perspectives on where each platform excels and how both will shape the future of genetic medicine. eu1.hubs.ly/H0tWsgJ0

Heading to Cell & Gene Meeting on the Med #CGMed26 in Italy? Our team will be there connecting with ATMP leaders to discuss how our next‑generation cell-free DNA can support faster, safer, and more scalable development across cell and gene therapy. eu1.hubs.ly/H0tSTkb0

With higher HDR efficiency, lower toxicity and scalable production,mbDNA™ is a breakthrough in non-viral, single-stranded DNA (ssDNA) technology. Reset your benchmark for gene therapy innovation. Get the expert insights here: eu1.hubs.ly/H0tNPjp0